Sol-Gel Technologies Ltd. Stock News

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, AMPH and SLGL.

NESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients wi

Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.26.

Sol-Gel Technologies Ltd. (SLGL) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.22.

NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an i

While the concept of high-risk speculation seems particularly dangerous at this juncture, gamblers may nevertheless want to consider the merits of targeting potentially lucrative biotech stocks that c

Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -92.31% and 94.60%, respectively, for the quarter ended December 2022.

Typically, penny stocks represent pure market wagers appropriate only for hardened gamblers. However, every once in a blue moon, a few ideas pop up in this segment that may be worth a genuine investme

The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.

SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of -114.29% and 92.44%, respectively, for the quarter ended September 2022.

The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.

SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 90% and 27.46%, respectively, for the quarter ended June 2022.

SolGel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 20% and 99.85%, respectively, for the quarter ended March 2022.

SolGel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

The impact of COVID-19 and continued pricing pressure on the Zacks Medical-Generic Drugs industry remains. New product launches may provide some respite for BHC, AMPH and SLGL.